Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML [0.03%]
BTX A51胶囊在血液系统恶性肿瘤(MDS和AML)患者中剂量递增的I期临床研究
Brian J Ball,Wenbin Xiao,Gautam Borthakur et al.
Brian J Ball et al.
Background: BTX A51, a first-in-class oral small molecule inhibitor of casein kinase 1α (CK1α) and cyclin-dependent kinase (CDK) 7 and 9, induces apoptosis of leukemic cells by activating p53 and inhibiting expression o...
Development and validation of a prognostic staging system for primary plasma cell leukemia [0.03%]
原发性浆细胞白血病预后分期系统的开发和验证
Mengru Tian,Gang An,Weijun Fu et al.
Mengru Tian et al.
Background: The existing risk models for multiple myeloma (MM) are suboptimal for the stratification of patients with primary plasma cell leukemia (pPCL), a rare and peculiar MM. In this study, we aimed to develop a stagi...
Multicenter Study
Journal of hematology & oncology. 2025 Jul 15;18(1):72. DOI:10.1186/s13045-025-01723-0 2025
Treatment-related adverse events of antibody drug-conjugates in clinical trials [0.03%]
抗体偶联药物临床试验相关不良反应事件分析
Harold Nathan Tan,Marta Ascanio Morcillo,Juanita Lopez et al.
Harold Nathan Tan et al.
Background: Antibody-drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden ...
Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance [0.03%]
单细胞和空间组学在解析癌药反应及耐药细胞特征方面的应用
Xiaoxia Cheng,Ting Peng,Tian Chu et al.
Xiaoxia Cheng et al.
Drug resistance poses a significant challenge in cancer therapy, contributing to rapid recurrence, disease progression, and high patient mortality. Despite its critical impact, few reliable predictors for cancer drug response or failure hav...
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia [0.03%]
靶向CCR9和CD1a的CAR-T细胞治疗T细胞急性淋巴细胞白血病
Néstor Tirado,Klaudyna Fidyt,María José Mansilla et al.
Néstor Tirado et al.
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy characterized by high rates of induction failure and relapse, and effective targeted immunotherapies are lacking. Despite promising clinical progress with genome-edited...
BRD4 acts as a transcriptional repressor of RhoB to inhibit terminal erythropoiesis [0.03%]
BRD4通过抑制RhoB表达负调控红系细胞终末分化
Yijin Chen,Dawei Huo,Ye Meng et al.
Yijin Chen et al.
Background: Terminal erythropoiesis is a complex multistep process involving coordination of gene transcription and dramatic nuclear condensation, which leads to the expulsion of nuclei to generate reticulocytes. However,...
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies [0.03%]
初治难治及复发弥漫性大B细胞淋巴瘤的治疗现状、 recent advances and emerging therapies
Allison M Bock,Narendranath Epperla
Allison M Bock
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy, that has had practice changing treatment approvals in both the frontline and relapsed setting in the last 5 years. Advent of novel therapeutic options in the re...
Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolution [0.03%]
单细胞分辨率解析胆管癌异质性和额外肝胆管癌祖细胞生态位
Chunliang Liu,Xiang Wang,Erdong Liu et al.
Chunliang Liu et al.
Background: Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy, primarily comprising intrahepatic (iCCA) and extrahepatic (eCCA) subtypes. Reconciling the variability between iCCAs and eCCAs in clinical trials ...
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy [0.03%]
肿瘤免疫调节的细胞外基质动力学：从肿瘤微环境到免疫治疗
Qin Hu,Yifei Zhu,Jie Mei et al.
Qin Hu et al.
The extracellular matrix (ECM), closely linked to the dynamic changes in the tumor microenvironment (TME), plays a critical role in modulating tumor immunity. The dual role of the ECM in tumor progression, encompassing both promotion and in...
Correction: Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy [0.03%]
订正：Ube2v1介导的Sirt1泛素化降解通过表观遗传抑制自噬促进结直肠癌转移
Tong Shen,Ling-Dong Cai,Yu-Hong Liu et al.
Tong Shen et al.
Published Erratum
Journal of hematology & oncology. 2025 Jun 17;18(1):64. DOI:10.1186/s13045-025-01719-w 2025